Clinical Trial

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Study acronym: P3BEP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2015-10-19; most recent amendment 2025-06-11.
Trial Details
NCT Number NCT02582697
Lead Sponsor University of Sydney
Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cambridge University Hospitals NHS Foundation Trust, Cancer Trials Ireland, Children's Oncology Group, Dana-Farber Cancer Institute, University of Southern California
Conditions Germ Cell Tumor
Enrollment 500 participants
Start Date 2014-02
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-15